Platelet-derived growth factor BB for the treatment of chronic pressure ulcers
- PMID: 1345953
- DOI: 10.1016/0140-6736(92)90143-q
Platelet-derived growth factor BB for the treatment of chronic pressure ulcers
Abstract
A randomised, phase I/II, double-blind, placebo-controlled study was designed to assess the effect of topically applied recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) on healing of chronic pressure ulcers. Twenty patients were randomly allocated daily treatment for 28 days with 1, 10, or 100 micrograms/ml rPDGF-BB (0.01, 0.1, or 1.0 micrograms per cm2 ulcer area) or placebo. Patients treated with 100 micrograms/ml rPDGF-BB showed a greater healing response than the placebo group, but the lower doses had little effect. After 28 days, ulcers treated with 100 micrograms/ml rPDGF-BB were smaller than those treated with placebo (mean [SE] volume 6.4 [4.0] vs 21.8 [5.6]% of day 0 volume). There were no toxic effects. These preliminary findings suggest that rPDGF-BB is a potent wound-healing agent in soft tissue.
Similar articles
-
A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.Arch Surg. 1994 Feb;129(2):213-9. doi: 10.1001/archsurg.1994.01420260109015. Arch Surg. 1994. PMID: 8304833 Clinical Trial.
-
Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.Ann Plast Surg. 1992 Sep;29(3):193-201. doi: 10.1097/00000637-199209000-00001. Ann Plast Surg. 1992. PMID: 1524367 Clinical Trial.
-
Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB.Am J Pathol. 1994 Dec;145(6):1399-410. Am J Pathol. 1994. PMID: 7992843 Free PMC article. Clinical Trial.
-
Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.Expert Opin Biol Ther. 2002 Feb;2(2):211-8. doi: 10.1517/14712598.2.2.211. Expert Opin Biol Ther. 2002. PMID: 11849120 Review.
-
Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.Am J Surg. 1998 Aug;176(2A Suppl):48S-54S. doi: 10.1016/s0002-9610(98)00177-9. Am J Surg. 1998. PMID: 9777972 Review.
Cited by
-
A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma.J Neurooncol. 2015 May;122(3):471-80. doi: 10.1007/s11060-015-1744-y. Epub 2015 Mar 4. J Neurooncol. 2015. PMID: 25732621 Free PMC article.
-
Age-related changes in wound healing.Drugs Aging. 2001;18(8):607-20. doi: 10.2165/00002512-200118080-00005. Drugs Aging. 2001. PMID: 11587247 Review.
-
Why menisci show higher healing rate when repaired during ACL reconstruction? Growth factors release can be the explanation.Knee Surg Sports Traumatol Arthrosc. 2015 Jan;23(1):90-6. doi: 10.1007/s00167-013-2712-8. Epub 2013 Oct 22. Knee Surg Sports Traumatol Arthrosc. 2015. PMID: 24146050
-
Minimizing Skin Scarring through Biomaterial Design.J Funct Biomater. 2017 Jan 21;8(1):3. doi: 10.3390/jfb8010003. J Funct Biomater. 2017. PMID: 28117733 Free PMC article. Review.
-
Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity.Virchows Arch. 1994;425(1):3-24. doi: 10.1007/BF00193944. Virchows Arch. 1994. PMID: 7921410 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical